Back to User profile » Dr Shu-Sen Wang

Papers published by Dr Shu-Sen Wang:


Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial

Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ

Breast Cancer: Targets and Therapy 2024, 16:223-231

Published Date: 12 April 2024

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus

Duan F, Song C, Ma Y, Jiang K, Xu F, Bi X, Huang J, Hong R, Huang Z, Lu Q, Yuan Z, Wang S, Xia W

Drug Design, Development and Therapy 2021, 15:3463-3473

Published Date: 10 August 2021

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis

Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang SS

Cancer Management and Research 2018, 10:2573-2580

Published Date: 14 August 2018

Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis

Yuan ZY, Dai T, Wang SS, Peng RJ, Li XH, Qin T, Song LB, Wang X

OncoTargets and Therapy 2014, 7:1733-1742

Published Date: 26 September 2014

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, Liu D, Wang S

OncoTargets and Therapy 2013, 6:341-347

Published Date: 9 April 2013